Table 1.

Demographic and clinical characteristics patient cohort.

	Multiple sclerosis patients
Demographic characteristics
N	179
Female, n (%)	136 (76%)
Age (years), mean (SD) [range]	38.12 ± 8.37 [18–63]
Age at onset (years), mean (SD) [range]	33.66 ± 8.51 [16–63]
Disease duration (years)
Mean (SD)	4.58 ± 4.13
Median [range]	3 [0–21]
Patients on DMT, n (%)
Yes	68 (38.0%)
No	57 (31.8%)
Unknown	54 (30.2%)
Clinical evaluation
MS classification, n (%)
RRMS	172 (96.1%)
PPMS	1 (0.6%)
SPMS	6 (3.3%)
EDSS, median [range]	3 [1.5–6]
Disease phase, n (%)
Stable	120 (67.0%)
Active	38 (21.3%)
Unknown	21 (11.7%)
Treatment type, n (%)
Off treatment	99 (55.3%)
Interferon-beta	49 (27.4%)
Glatiramer acetate	25 (14.0%)
Tysabri	6 (3.3%)

SD, standard deviation; DMT, disease modifying treatments, use on moment of blood sampling; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive multiple sclerosis; EDSS, expanded disability scale status at study assessment; Active Disease Phase, enhanced lesions are present and the patient suffered ≥ 2 Relapses in the year before study enrolment; Unknown Disease Phase, the amount of relapses in the past year is unknown and/or the presence of enhanced lesions is unknown; Stable Disease Phase, the amount of relapses in the past year is <2 and/or enhanced lesions are not present. Treatment Type was registered at the start of study enrolment.